Back to News
Market Impact: 0.25
SL Science Reports Promising Targeting Of Cancer Cells By Gamma-Omega T Cells
Source: Nasdaq
Healthcare & BiotechTechnology & Innovation
SL Science Holding announced positive preclinical data for gamma-omega T-cell therapy in glioblastoma, presented at the 85th Annual Meeting of the Japanese Cancer Association. The early-stage results support the company’s oncology development program, though clinical efficacy, regulatory progress, and commercialization remain unproven.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.38
More News
- Anthropic CEO Amodei to have dinner with Trump at White House
- Here are the 4 big things we're watching in the stock market in the week ahead
- ‘China has arrived’: From $1,000 Gucci sneakers to German cars, China is coming for the industries that made Europe rich
- OpenAI, Anthropic CEOs called to appear at Australian AI probe
- Apple, Microsoft, and Meta prove stock picking for individuals is not a fool's errand
- Amazon evaluating drone deliveries in Australia, Asia
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience
- How to Build an Automated Research Process for a Fund